Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
Standard
Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. / Busch, Jonas; Seidel, Christoph; Goranova, Irena; Erber, Barbara; Peters, Robert; Friedersdorff, Frank; Magheli, Ahmed; Miller, Kurt; Grünwald, Viktor; Weikert, Steffen.
In: EUR J CANCER, Vol. 50, No. 3, 2014, p. 563-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
AU - Busch, Jonas
AU - Seidel, Christoph
AU - Goranova, Irena
AU - Erber, Barbara
AU - Peters, Robert
AU - Friedersdorff, Frank
AU - Magheli, Ahmed
AU - Miller, Kurt
AU - Grünwald, Viktor
AU - Weikert, Steffen
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2014
Y1 - 2014
N2 - INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS.MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS .RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS.CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.
AB - INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS.MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS .RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS.CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.
U2 - 10.1016/j.ejca.2013.10.017
DO - 10.1016/j.ejca.2013.10.017
M3 - SCORING: Journal article
C2 - 24239449
VL - 50
SP - 563
EP - 569
JO - EUR J CANCER
JF - EUR J CANCER
SN - 0959-8049
IS - 3
ER -